Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In major depressive disorder (MDD), the traditional belief of a delayed onset of antidepressants' effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks before medication change in case of insufficient outcome. Post hoc analyses of clinical trials, however, have shown that improvement usually occurs within the first 10-14 days of treatment and that such early improvement (Hamilton Depression Rating Scale [HAMD] decrease >or=20%) has a substantial predictive value for final treatment outcome. Even more important, non-improvement (HAMD decrease <20%) after 14 days of treatment was found to be highly predictive for a poor final treatment outcome. METHODS/DESIGN: The EMC trial is a phase IV, multi-centre, multi-step, randomized, observer-blinded, actively controlled parallel-group clinical trial to investigate for the first time prospectively, whether non-improvers after 14 days of antidepressant treatment with an early medication change (EMC) are more likely to attain remission (HAMD-17 <or=7) on treatment day 56 compared to patients treated according to current guideline recommendation (treatment as usual; TAU). In level 1 of the EMC trial, non-improvers after 14 days of antidepressant treatment will be randomised to an EMC strategy or TAU. The EMC strategy for this study schedules a first medication change on day 15; in case of non-improvement between days 15-28, a second medication change will be performed. TAU schedules the first medication change after 28 days in case of non-response (HAMD-17 decrease <50%). Both interventions will last 42 days. In levels 2 and 3, EMC strategies will be compared with TAU strategies in improvers on day 14, who experience a stagnation of improvement during the course of treatment. The trial is supported by the German Federal Ministry of Education and Research (BMBF) and will be conducted in cooperation with the BMBF funded Interdisciplinary Centre Clinical Trials (IZKS) at the University Medical Centre Mainz and at six clinical trial sites in Germany. DISCUSSION: If the EMC strategies lead to significantly more remitters, changes of clinical practice, guidelines for the treatment of MDD as well as research settings can be expected. TRIAL REGISTRATION: Clincaltrials.gov Identifier: NCT00974155; EudraCT: 2008-008280-96.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 1×
“... 2 and 3 of the EMC trial, further secondary endpoints will be assessed: time to remission and time to response according to IDS and HAMD17; remission from MDD, defined as HAMD17 sum score ≤ 7o n day 56 (in subgroups of improvers on day 14 entering level 2 or level 3 of The EMC trial); absolute change in SF-12 subs…”
MethodCipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“The switch from escitalopram to venlafaxine led to a remission in 24% after 14 weeks of treatment [38]; for the treatment period of this trial (day 29-56), we assume a remission rate of 20% on day 56 for TAU 1.”
BackgroundTaylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406 · cited 1×
“All current evidences originate from retrospective data analysis, but not from prospective clinical trials: there is substantial evidence showing that non-improvement in the first 2 weeks of AD treatment is highly predictive for poor final outcome and leading experts in the field have repeatedly recommended the outcom…”
BackgroundSzegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03780 · Cited by 341
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252 · cited 1×
“Katz and colleagues reported on a randomised controlled trial (RCT) in which patients were treated with the selelctive serotonin reuptake inhibitor paroxetine, the tricyclic antidepressant desipramine or placebo [20].”
Background
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…within the fi rst 14 days of treatment (Nierenberg et al. 2000; Szegedi et al. 2003; Katz et al. 2004; Posternak and Zimmerman 2005; Papakostas et al. 2006; Taylor et al. 2006; Stassen et al. 2007; Henkel et al. 2009; Hennings et al. 2009; Szegedi et al. 2009; Tadic et al. 2010b; Uher et al. 2010).”
BackgroundWagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., Tadić, A., & Lieb, K. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.07.003 · Cited by 73
Lieb, K., Dreimüller, N., Wagner, S., Schlicht, K., Falter, T., Neyazi, A., Müller-Engling, L., Bleich, S., Tadić, A., & Frieling, H. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00511 · Cited by 54
“Demographic parameters (age, sex, ethnicity) and psychiatric history (number of preceding depressive episodes, length of index episode, age at onset, clinical course) were assessed relying on patients’ self-reports (41, 42).”
MethodSelf-citationEngelmann, J., Zillich, L., Frank, J., Wagner, S., Cetin, M., Herzog, D. P., Müller, M. B., Tadic, A., Foo, J. C., Sirignano, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02032-7 · Cited by 29
Self-citation
Metadata
- Authors
- the EMC Study Group, Tadić, A., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., Röschke, J., van Calker, D., Wachtlin, D., Kronfeld, K., Gorbauch, T., Seibert-Grafe, M., & Lieb, K.
- Venue
- Trials
- Published
- 2010-02-26
- Volume
- 11
- Issue
- 1
- Pages
- 21-21
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2163997752
- Cited by
- 29
- References
- 14
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial. https://app.cochat.ai/papers/10.1186/1745-6215-11-21
- The paper
- the EMC Study Group, Tadić, A., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., Röschke, J., van Calker, D., Wachtlin, D., Kronfeld, K., Gorbauch, T., Seibert-Grafe, M., & Lieb, K. (2010). Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial. Trials. https://doi.org/10.1186/1745-6215-11-21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.